Nowadays, we are living longer and better in Switzerland because the population is benefiting from innovative medicinal products and has access to high-quality healthcare. Yet there is a need for action and improvement in a number of areas, and there are new challenges that are in urgent need of solutions. These include, for example, promotion of a world-leading ecosystem for health data, flexible reimbursement models for innovations and more intensive cooperation with the authorities.
3 Questions to Colleen Kamrad - Vice President and General Manager of GSK Switzerland
3 Questions to Leila Schwery-Bou-Diab - VP Manufacturing & Technical Operations Janssen, Johnson & Johnson
Interview with René Buholzer: "The challenge for the future of innovation in Switzerland and for Swiss pharma companies in general is to once again adapt to technological changes"
Quality before costs, less willingness to do without
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2020
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives